1. Effects of Soft Tissue Sarcoma and Doxorubicin on Bone Metabolism in Mice.
- Author
-
FUMIHITO KASAMA, HIROYUKI TSUCHIE, HIROYUKI NAGASAWA, MICHIO HONGO, YUJI KASUKAWA, KOJI NOZAKA, DAISUKE KUDO, RYO SHOJI, SHUN IGARASHI, SHUNTARO HARATA, KENTO OKAMOTO, KEITA OYA, and NAOHISA MIYAKOSHI
- Subjects
SOFT tissue tumors ,DOXORUBICIN ,BONE metabolism ,OSTEOPOROSIS treatment ,COMPUTED tomography - Abstract
Background/Aim: This study aimed to evaluate the effects of doxorubicin (Dox) on bone microstructure and metabolism in a mouse model of soft tissue sarcoma. Materials and Methods: CCRF S-180? cells (2-4×105 cells/0.2 ml) were injected subcutaneously into the back of mice. The mice were divided into four groups according to tumor and treatment status and were reared and sacrificed after 2 or 4 weeks. Micro-computed tomography (CT) was performed to calculate the architecture of the femoral bone. The proximal tibia was double stained with tartrate-resistant acid phosphatase (TRACP) and alkaline phosphatase (ALP), and bone morphometry was performed. Results: Trabecular bone mass was significantly reduced in the Sarcoma and Sarcoma+Dox groups. Cortical bone thickness was reduced in the DOX group, with a stronger effect observed in the Sarcoma+Dox group. In bone morphometry, osteoclast number at the bone surface (Oc.N/BS) was significantly lower in the Dox, Sarcoma, and Sarcoma+Dox groups than in the Control group at 2 weeks. The osteoblast surface at the bone surface (Ob.S/BS) was significantly lower in the Dox and Sarcoma groups than in the Control group at 2 weeks. At 4 weeks, the differences were smaller for both Oc.N/BS and Ob.S/BS. Conclusion: The use of doxorubicin alone worsened the cortical bone structure; however, the presence of both soft-tissue sarcoma and doxorubicin use worsened both cortical and trabecular bone structures from an early stage. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF